Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Ironwood Pharmaceuticals Debt to Equity Ratio 2010-2025 | IRWD

Current and historical debt to equity ratio values for Ironwood Pharmaceuticals (IRWD) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Ironwood Pharmaceuticals debt/equity for the three months ending March 31, 2025 was 0.00.
  
Ironwood Pharmaceuticals Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2025-03-31 $0.66B $-0.33B -1.98
2024-12-31 $0.65B $-0.30B -2.17
2024-09-30 $0.70B $-0.31B -2.25
2024-06-30 $0.72B $-0.32B -2.23
2024-03-31 $0.77B $-0.33B -2.33
2023-12-31 $0.82B $-0.35B -2.36
2023-09-30 $0.85B $-0.33B -2.61
2023-06-30 $0.95B $-0.35B -2.74
2023-03-31 $0.45B $0.71B 0.63
2022-12-31 $0.45B $0.65B 0.69
2022-09-30 $0.45B $0.59B 0.76
2022-06-30 $0.44B $0.53B 0.83
2022-03-31 $0.57B $0.52B 1.09
2021-12-31 $0.52B $0.61B 0.86
2021-09-30 $0.50B $0.58B 0.86
2021-06-30 $0.50B $0.51B 0.97
2021-03-31 $0.49B $0.11B 4.44
2020-12-31 $0.50B $0.06B 7.93
2020-09-30 $0.49B $0.01B 82.39
2020-06-30 $0.48B $-0.04B -13.04
2020-03-31 $0.48B $-0.07B -6.65
2019-12-31 $0.50B $-0.09B -5.32
2019-09-30 $0.49B $-0.15B -3.19
2019-06-30 $0.54B $-0.22B -2.44
2019-03-31 $0.60B $-0.24B -2.53
2018-12-31 $0.53B $-0.20B -2.69
2018-09-30 $0.61B $-0.20B -3.11
2018-06-30 $0.66B $-0.04B -15.07
2018-03-31 $0.59B $-0.02B -32.64
2017-12-31 $0.60B $0.01B 60.50
2017-09-30 $0.64B $-0.02B -36.56
2017-06-30 $0.70B $0.01B 143.78
2017-03-31 $0.67B $0.03B 22.66
2016-12-31 $0.64B $0.07B 9.64
2016-09-30 $0.67B $0.06B 11.31
2016-06-30 $0.62B $0.08B 7.60
2016-03-31 $0.51B $0.09B 5.64
2015-12-31 $0.52B $0.10B 5.51
2015-09-30 $0.51B $0.10B 5.11
2015-06-30 $0.51B $0.14B 3.66
2015-03-31 $0.24B $0.07B 3.48
2014-12-31 $0.24B $0.09B 2.72
2014-09-30 $0.24B $0.11B 2.20
2014-06-30 $0.23B $0.14B 1.62
2014-03-31 $0.23B $0.19B 1.22
2013-12-31 $0.24B $0.04B 6.30
2013-09-30 $0.24B $0.08B 2.87
2013-06-30 $0.25B $0.14B 1.76
2013-03-31 $0.27B $0.06B 4.56
2012-12-31 $0.09B $0.14B 0.60
2012-09-30 $0.06B $0.18B 0.35
2012-06-30 $0.08B $0.13B 0.62
2012-03-31 $0.09B $0.16B 0.52
2011-12-31 $0.10B $0.11B 0.90
2011-09-30 $0.11B $0.11B 0.94
2011-06-30 $0.12B $0.13B 0.92
2011-03-31 $0.13B $0.15B 0.88
2010-12-31 $0.14B $0.16B 0.89
2010-09-30 $0.14B $0.17B 0.81
2010-06-30 $0.15B $0.17B 0.86
2010-03-31 $0.15B $0.19B 0.79
2009-12-31 $0.46B $-0.30B -1.55
2009-09-30 $0.43B $-0.28B -1.54
2009-06-30 $0.00B $0.00B 0.00
2009-03-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $0.098B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) Japan $86.949B 32.62
Zoetis (ZTS) United States $75.757B 28.27
Takeda Pharmaceutical (TAK) Japan $47.602B 9.47
Daiichi Sankyo, - (DSNKY) Japan $46.162B 23.49
Sandoz Group AG (SDZNY) Switzerland $23.544B 0.00
Merck (MKKGY) Germany $16.989B 12.45
Summit Therapeutics (SMMT) United States $15.291B 0.00
United Therapeutics (UTHR) United States $14.697B 13.00
Shionogi (SGIOY) Japan $14.292B 14.32
Neurocrine Biosciences (NBIX) United States $12.409B 42.51
IPSEN (IPSEY) France $10.165B 0.00
Orion OYJ (ORINY) Finland $10.083B 27.27
Corcept Therapeutics (CORT) United States $7.381B 60.00
Stevanato Group S.p.A (STVN) Italy $7.189B 43.96
Madrigal Pharmaceuticals (MDGL) United States $6.178B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $6.153B 0.00
Grifols, S.A (GRFS) Spain $6.064B 0.00
Ionis Pharmaceuticals (IONS) United States $5.617B 0.00
Ono Pharmaceutical (OPHLF) Japan $4.913B 14.94
Soleno Therapeutics (SLNO) United States $3.805B 0.00
Catalyst Pharmaceuticals (CPRX) United States $3.155B 11.06
Crinetics Pharmaceuticals (CRNX) United States $3.091B 0.00
Hypermarcas (HYPMY) Brazil $2.958B 19.46
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $2.388B 12.92
BioCryst Pharmaceuticals (BCRX) United States $2.310B 0.00
NewAmsterdam Pharma (NAMS) Netherlands $2.261B 0.00
Recursion Pharmaceuticals (RXRX) United States $2.232B 0.00
Indivior (INDV) United States $1.940B 8.23
Dyne Therapeutics (DYN) United States $1.671B 0.00
Centessa Pharmaceuticals (CNTA) United Kingdom $1.592B 0.00
Evotec AG (EVO) Germany $1.438B 0.00
Ocular Therapeutix (OCUL) United States $1.437B 0.00
ARS Pharmaceuticals (SPRY) United States $1.423B 0.00
Guardian Pharmacy Services (GRDN) United States $1.307B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $1.107B 22.14
Harrow (HROW) United States $1.086B 0.00
Akebia Therapeutics (AKBA) United States $1.043B 0.00
Enliven Therapeutics (ELVN) United States $1.018B 0.00
Collegium Pharmaceutical (COLL) United States $0.970B 5.23
Avadel Pharmaceuticals (AVDL) Ireland $0.940B 0.00
Ardelyx (ARDX) United States $0.880B 0.00
Cronos Group (CRON) Canada $0.764B 0.00
Xeris Biopharma Holdings (XERS) United States $0.716B 0.00
KalVista Pharmaceuticals (KALV) United States $0.714B 0.00
Xencor (XNCR) United States $0.687B 0.00
Liminatus Pharma (LIMN) United States $0.630B 0.00
Elite Pharmaceuticals (ELTP) United States $0.620B 0.00
AleAnna (ANNA) United States $0.617B 0.00
Relay Therapeutics (RLAY) United States $0.576B 0.00
Regulus Therapeutics (RGLS) United States $0.569B 0.00
Theravance Biopharma (TBPH) United States $0.563B 0.00
Verve Therapeutics (VERV) United States $0.552B 0.00
Bioventus (BVS) United States $0.550B 13.94
USANA Health Sciences (USNA) United States $0.547B 11.89
Zevra Therapeutics (ZVRA) United States $0.506B 0.00
Tourmaline Bio (TRML) United States $0.495B 0.00
Amylyx Pharmaceuticals (AMLX) United States $0.475B 0.00
Oruka Therapeutics (ORKA) United States $0.471B 0.00
Altimmune (ALT) United States $0.456B 0.00
Siga Technologies (SIGA) United States $0.431B 9.00
Savara (SVRA) United States $0.422B 0.00
Organogenesis (ORGO) United States $0.384B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.384B 10.38
Aquestive Therapeutics (AQST) United States $0.354B 0.00
Heron Therapeutics (HRTX) United States $0.320B 0.00
Tonix Pharmaceuticals Holding (TNXP) United States $0.298B 0.00
ProKidney (PROK) United States $0.286B 0.00
Nature's Sunshine Products (NATR) United States $0.266B 24.59
Esperion Therapeutics (ESPR) United States $0.242B 0.00
MediWound (MDWD) Israel $0.233B 0.00
Nanobiotix S.A (NBTX) France $0.222B 0.00
4D Molecular Therapeutics (FDMT) United States $0.202B 0.00
Lyell Immunopharma (LYEL) United States $0.189B 0.00
OmniAb (OABI) United States $0.183B 0.00
Journey Medical (DERM) United States $0.172B 0.00
Larimar Therapeutics (LRMR) United States $0.172B 0.00
Profound Medical (PROF) Canada $0.167B 0.00
Aclaris Therapeutics (ACRS) United States $0.166B 0.00
Avita Medical (RCEL) United States $0.162B 0.00
Enanta Pharmaceuticals (ENTA) United States $0.160B 0.00
Aldeyra Therapeutics (ALDX) United States $0.159B 0.00
Inhibikase Therapeutics (IKT) United States $0.146B 0.00
Korro Bio (KRRO) United States $0.137B 0.00
Achieve Life Sciences (ACHV) Canada $0.133B 0.00
Lexeo Therapeutics (LXEO) United States $0.129B 0.00
Protara Therapeutics (TARA) United States $0.129B 0.00
Nektar Therapeutics (NKTR) United States $0.124B 0.00
Innate Pharma SA (IPHYF) France $0.122B 0.00
Wellgistics Health (WGRX) United States $0.121B 0.00
Cardiol Therapeutics (CRDL) Canada $0.117B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.113B 0.00
Cassava Sciences (SAVA) United States $0.106B 0.00
Fractyl Health (GUTS) United States $0.097B 0.00
OptiNose (OPTN) United States $0.097B 0.00
Champions Oncology (CSBR) United States $0.095B 15.66
VAXART, INC (VXRT) United States $0.093B 0.00
Inotiv (NOTV) United States $0.092B 0.00
Unicycive Therapeutics (UNCY) United States $0.091B 0.00
Arch Biopartners (ACHFF) Canada $0.089B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.087B 64.67
Nutriband (NTRB) United States $0.086B 0.00
Pyxis Oncology (PYXS) United States $0.084B 0.00
Galectin Therapeutics (GALT) United States $0.084B 0.00
Dominari Holdings (DOMH) United States $0.079B 0.00
ESSA Pharma (EPIX) Canada $0.076B 0.00
Surrozen (SRZN) United States $0.073B 0.00
Vivani Medical (VANI) United States $0.068B 0.00
Metagenomi (MGX) United States $0.065B 0.00
Telomir Pharmaceuticals (TELO) United States $0.064B 0.00
Assertio Holdings (ASRT) United States $0.063B 0.00
Context Therapeutics (CNTX) United States $0.060B 0.00
Allergy Therapeutics (AGYTF) United Kingdom $0.059B 0.00
Prelude Therapeutics (PRLD) United States $0.058B 0.00
Gain Therapeutics (GANX) United States $0.058B 0.00
Verrica Pharmaceuticals (VRCA) United States $0.057B 0.00
NRx Pharmaceuticals (NRXP) United States $0.057B 0.00
Century Therapeutics (IPSC) United States $0.053B 0.00
PMV Pharmaceuticals (PMVP) United States $0.050B 0.00
Rafael Holdings (RFL) United States $0.047B 0.00
Avalo Therapeutics (AVTX) United States $0.044B 0.00
Mural Oncology (MURA) Ireland $0.044B 0.00
ElectroCore (ECOR) United States $0.043B 0.00
Acrivon Therapeutics (ACRV) United States $0.042B 0.00
Iterum Therapeutics (ITRM) Ireland $0.039B 0.00
Karyopharm Therapeutics (KPTI) United States $0.039B 0.00
Reviva Pharmaceuticals Holdings (RVPH) United States $0.038B 0.00
SCYNEXIS (SCYX) United States $0.036B 0.00
PolyPid (PYPD) Israel $0.033B 0.00
China SXT Pharmaceuticals (SXTC) China $0.033B 0.00
Lyra Therapeutics (LYRA) United States $0.032B 0.00
FibroGen (FGEN) United States $0.032B 0.00
Tempest Therapeutics (TPST) United States $0.030B 0.00
Relmada Therapeutics (RLMD) United States $0.028B 0.00
Jupiter Neurosciences (JUNS) United States $0.026B 0.00
CASI Pharmaceuticals (CASI) China $0.023B 0.00
Enlivex Therapeutics (ENLV) Israel $0.023B 0.00
Natural Alternatives (NAII) United States $0.021B 0.00
Mannatech (MTEX) United States $0.020B 0.00
BioVie (BIVI) United States $0.020B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.020B 0.00
BioLineRx (BLRX) Israel $0.019B 0.00
Lipocine (LPCN) United States $0.017B 0.00
DURECT (DRRX) United States $0.017B 0.00
VYNE Therapeutics (VYNE) United States $0.015B 0.00
ProPhase Labs (PRPH) United States $0.015B 0.00
TherapeuticsMD (TXMD) United States $0.014B 0.00
Phio Pharmaceuticals (PHIO) United States $0.014B 0.00
Scienture Holdings (SCNX) United States $0.014B 0.00
Ainos (AIMD) United States $0.014B 0.00
Cosmos Health (COSM) United States $0.014B 0.00
Vivos Therapeutics (VVOS) United States $0.013B 0.00
Minerva Neurosciences (NERV) United States $0.013B 2.24
GlycoMimetics (GLYC) United States $0.013B 0.00
Ernexa Therapeutics (ERNA) United States $0.011B 0.00
Addex Therapeutics (ADXN) Switzerland $0.011B 0.00
Mangoceuticals (MGRX) United States $0.011B 0.00
Talphera (TLPH) United States $0.010B 0.00
Kiora Pharmaceuticals (KPRX) United States $0.009B 0.00
Traws Pharma (TRAW) United States $0.009B 0.00
SHINECO (SISI) China $0.009B 0.00
Biomerica (BMRA) United States $0.009B 0.00
Citius Pharmaceuticals (CTXR) United States $0.008B 0.00
NLS Pharmaceutics (NLSP) Switzerland $0.008B 0.00
Carisma Therapeutics (CARM) United States $0.008B 0.00
Nuvilex (PMCB) United States $0.007B 0.00
Klotho Neurosciences (KLTO) United States $0.007B 0.00
XTL Biopharmaceuticals (XTLB) Israel $0.006B 0.00
TransCode Therapeutics (RNAZ) United States $0.006B 0.00
Aptorum Group (APM) United Kingdom $0.006B 0.00
Plus Therapeutics (PSTV) United States $0.006B 0.00
Indaptus Therapeutics (INDP) United States $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.005B 0.00
Incannex Healthcare (IXHL) Australia $0.005B 0.00
Quoin Pharmaceuticals (QNRX) United States $0.005B 0.00
Alaunos Therapeutics (TCRT) United States $0.005B 0.00
Redhill Biopharma (RDHL) Israel $0.005B 0.00
Xenetic Biosciences (XBIO) United States $0.005B 0.00
60 Degrees Pharmaceuticals (SXTP) United States $0.004B 0.00
PainReform (PRFX) Israel $0.004B 0.00
Jaguar Animal Health (JAGX) United States $0.004B 0.00
Clearmind Medicine (CMND) Canada $0.004B 0.00
Heatwurx (PCSA) United States $0.004B 0.00
CERo Therapeutics Holdings (CERO) United States $0.004B 0.00
XORTX Therapeutics (XRTX) Canada $0.003B 0.00
InMed Pharmaceuticals (INM) Canada $0.003B 0.00
SciSparc (SPRC) Israel $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) United States $0.003B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.003B 0.00
TNF Pharmaceuticals (TNFA) United States $0.002B 0.00
Conduit Pharmaceuticals (CDT) United States $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) United States $0.002B 0.00
Salarius Pharmaceuticals (SLRX) United States $0.002B 0.00
Universe Pharmaceuticals INC (UPC) China $0.000B 0.00
4D Pharma (LBPS) United Kingdom $0.000B 0.00
MEI Pharma (MEIP) United States $0.000B 0.00
Patheon (PTHN) Netherlands $0.000B 0.00
RVL Pharmaceuticals (RVLP) United States $0.000B 0.00
Silence Therapeutics (SLN) United Kingdom $0.000B 0.00